Efficacy and Safety Study of Abnoba Viscum F 20mg in Malignant Pleural Effusion Patients

A Phase 3, Multi-Center, Single-Arm, Open-Label Study For The Safety And Efficacy Of Mistletoe Extract (AbnobaViscum® Injection) In Malignant Pleural Effusions

Phase 3, non-randomized, Multicenter, single arm study to assess efficacy and safety of Abnoba viscum F 20mg in patients with malignant pleural effusion

Inclusion Criteria:

• Subject who need the pleurodesis among subjects diagnosed with a mlignant pleural effusion
• Full lung expansion must be achieved within 12 to 24 hours after drainage
• Expected survival time of at least 2 months
• Subject who score 50 or more on the Karnofsky Performance Scale

Exclusion Criteria:

• Subjects with previous attempts at pleurodesis with sclerosing agent
• Subjects with trapped lung or bronchial obstruction
• Subjects with adverse drug response to mistletoe agents
• Subjects who have participated in another clinical study other than the present study
• Subjects who is taking immune-suppressive agents
• Subjects with medical and psychiatric contraindications for the study drug
• Subjects who are not allowed to participate in the study by legal requirement
• Subjects who are not allowed to participate in the study by the Investigator's discretion